PMID- 15933481
OWN - NLM
STAT- MEDLINE
DCOM- 20051004
LR  - 20211203
IS  - 0268-1315 (Print)
IS  - 0268-1315 (Linking)
VI  - 20
IP  - 4
DP  - 2005 Jul
TI  - Lack of impact of race on the efficacy and safety of long-acting risperidone 
      versus placebo in patients with schizophrenia or schizoaffective disorder.
PG  - 207-12
AB  - This analysis aimed to assess the relationship between race and clinical response 
      to long-acting, injectable risperidone treatment in patients with schizophrenia 
      or schizoaffective disorder. In a 12-week, randomized, double-blind study, 
      patients with schizophrenia or schizoaffective disorder received placebo or 
      long-acting risperidone (25, 50 or 75 mg every 2 weeks). Data were stratified by 
      race as identified by demographic information: Caucasian, African-American or 
      Other. Psychotic symptoms were assessed by the Positive and Negative Syndrome 
      Scale (PANSS); movement disorders by the Extrapyramidal Symptom Rating Scale 
      (ESRS); adverse events (AEs) were reported spontaneously. Data were available for 
      439 patients: 193 Caucasian (44%), 174 (40%) African-American and 72 (16%) Other 
      patients. Baseline characteristics were similar between racial groups, as were 
      study completion rates (overall: 30% placebo; 48% long-acting risperidone). There 
      was a significant effect of treatment (P<0.001), but not of race, on improvement 
      in PANSS total scores from baseline to endpoint. ESRS scores were low throughout 
      the study, and no significant impact of race was observed. Overall rates of AEs 
      were similar among the racial groups. Race did not appear to impact the efficacy 
      and tolerability of long-acting risperidone.
FAU - Ciliberto, Natalie
AU  - Ciliberto N
AD  - Medical Services CNS, Medical Affairs Division, Janssen Pharmaceutica, Inc, 
      Titusville, New Jersey 08560, USA. nciliber@janus.jnj.com
FAU - Bossie, Cynthia A
AU  - Bossie CA
FAU - Urioste, Ronald
AU  - Urioste R
FAU - Lasser, Robert A
AU  - Lasser RA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Placebos)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/*adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Psychotic Disorders/*drug therapy/*ethnology
MH  - *Racial Groups
MH  - Risperidone/administration & dosage/*adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy/*ethnology
MH  - Treatment Outcome
EDAT- 2005/06/04 09:00
MHDA- 2005/10/05 09:00
CRDT- 2005/06/04 09:00
PHST- 2005/06/04 09:00 [pubmed]
PHST- 2005/10/05 09:00 [medline]
PHST- 2005/06/04 09:00 [entrez]
AID - 00004850-200507000-00003 [pii]
AID - 10.1097/00004850-200507000-00003 [doi]
PST - ppublish
SO  - Int Clin Psychopharmacol. 2005 Jul;20(4):207-12. doi: 
      10.1097/00004850-200507000-00003.